Bouvier Nicolas, Trenque T, Millart H
Laboratoire de pharmacologie-toxicologie, Hôpital Maison-Blanche, CHU, 45, rue Cognacq-Jay 51092 Reims.
Presse Med. 2003 Mar 22;32(11):519-22.
The first antidepressants were developed after the discovery of the existence during depression of a perturbation in the synaptic transmission of the principle monoamines: noradrenalin, serotonin and dopamine. The pharmacological effect of the various molecules developed is mainly on the metabolisation routes of neurotransmitters, but may also concern the different receptors present on synaptic level. THE AWARENESS OF NEW MEDIATORS: The progress in research on antidepressants has widened the scope of the development of such medicinal products to the domain of endocrinology (hypothalamo-pituitary-adrenal axis, progestogen hormones, thyreotropic axis) and studies on neuropeptides (substance P, neuropeptide Y). The complexity of the physiopathological mechanisms of depression hence appears enhanced.
在发现抑郁症期间主要单胺类神经递质(去甲肾上腺素、血清素和多巴胺)的突触传递存在紊乱后,首批抗抑郁药得以研发。所研发的各种分子的药理作用主要针对神经递质的代谢途径,但也可能涉及突触水平上存在的不同受体。对新介质的认识:抗抑郁药研究的进展已将此类药品的研发范围扩展至内分泌学领域(下丘脑 - 垂体 - 肾上腺轴、孕激素、促甲状腺轴)以及神经肽研究(P物质、神经肽Y)。因此,抑郁症生理病理机制的复杂性似乎有所增强。